Browse FUT4

Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Note=Membrane-bound form in trans cisternae of Golgi.
Domain PF17039 Fucosyltransferase
PF00852 Glycosyltransferase family 10 (fucosyltransferase) C-term
Function

May catalyze alpha-1,3 glycosidic linkages involved in the expression of Lewis X/SSEA-1 and VIM-2 antigens.

> Gene Ontology
 
Biological Process GO:0005996 monosaccharide metabolic process
GO:0006004 fucose metabolic process
GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0016052 carbohydrate catabolic process
GO:0019317 fucose catabolic process
GO:0019318 hexose metabolic process
GO:0019320 hexose catabolic process
GO:0036065 fucosylation
GO:0042354 L-fucose metabolic process
GO:0042355 L-fucose catabolic process
GO:0043413 macromolecule glycosylation
GO:0044282 small molecule catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046365 monosaccharide catabolic process
GO:0070085 glycosylation
Molecular Function GO:0008417 fucosyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016758 transferase activity, transferring hexosyl groups
GO:0046920 alpha-(1->3)-fucosyltransferase activity
Cellular Component GO:0005795 Golgi stack
GO:0031984 organelle subcompartment
GO:0031985 Golgi cisterna
GO:0032580 Golgi cisterna membrane
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa00601 Glycosphingolipid biosynthesis - lacto and neolacto series
hsa01100 Metabolic pathways
Reactome -
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FUT4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FUT4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25024303lymphomaInhibit immunity (infiltration)The serum absolute lymphocyte count, the presence of tumor-infiltrating dendritic cells, CD15 expression on the malignant cells, and tumor morphology were biomarkers of outcome in MGZL.
21480223Bladder CarcinomaInhibit immunityOur results demonstrate that PBMC from bladder cancer patients contain two major CD11b myeloid cell subsets: granulocyte-type CD15(high) CD33(low) cells and monocyte-type CD15(low) CD33(high) cells. Granulocytic myeloid cells were able to inhibit in vitro T cell proliferation through induction of CD4(+) Foxp3(+) T regulatory cells.
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FUT4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FUT4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8060.00804
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8290.232
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7970.204
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1870.696
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1970.893
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6720.71
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1990.526
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2550.801
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.120.916
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1290.842
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.230.818
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.050.732
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FUT4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FUT4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FUT4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FUT4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FUT4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FUT4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FUT4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFUT4
Namefucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific)
Aliases FUC-TIV; ELAM ligand fucosyltransferase; CD15; ELFT; FUTIV; LeX; SSEA-1; ELAM-1 ligand fucosyltransferase; L ......
Chromosomal Location11q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FUT4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.